Loading patent…
AssigneesTaisho Pharmaceutical Co., Ltd., Akemichi BABA
InventorsAkemichi Baba, Hitoshi Hashimoto, Norihito Shintani, Yukihiko Sugimoto
Estimating the term…
There are provided PACAP which is a substance capable of inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells, a method for inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells in a human by PACAP administration, a pharmaceutical composition containing PACAP and, optionally, an anti-diabetic agent, and a method for evaluating a substance capable of inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells relying on the expression of Reg IIIβ to be stimulated by PACAP as an index.
A method for inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells in a human showing such symptom and in need of inhibition thereof, the method comprises administering to the human, an inhibition effective amount of pituitary adenylate cyclase-activating peptide.
An inhibitor of the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells comprising pituitary adenylate cyclase-activating peptide.
A pharmaceutical composition for inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells comprising an effective amount of pituitary adenylate cyclase-activating peptide and a pharmaceutically acceptable carrier.
A method for preventing or treating a patient afflicted with diabetes and in need of such treatment or a patient suspected of developing diabetes, the method comprising administering to the patient, pituitary adenylate cyclase-activating peptide and one or more agents selected from a biguanide drug, an α-glucosidase inhibitor, a thiazoline derivative or a sulfonylurea drug.
A prophylactic or therapeutic agent for diabetes comprising pituitary adenylate cyclase-activating peptide and one or more agents selected from a biguanide drug, an α-glucosidase inhibitor, a thiazoline derivative or a sulfonylurea drug.
A pharmaceutical composition comprising pituitary adenylate cyclase-activating peptide characterized by being used simultaneously, separately or consecutively together with a pharmaceutical composition comprising as the effective agent, one or more agents selected from a biguanide drug, an α-glucosidase inhibitor, a thiazoline derivative or a sulfonylurea drug in the prevention or treatment of diabetes.
A method for evaluating a substance capable of inhibiting the hyperplasia of pancreatic cells and/or the hypersecretion of insulin by pancreatic cells, the method comprising contacting a substance to be assayed with a cell expressing Reg IIIβ and employing as an index, any change in the expression of Reg IIIβ upon the contact.
Dependencies are inferred from the claim text.